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 Abstract 24 
Background:  Bisphosphonates (BPs), the gold-standard pharmacological treatment for 25 
osteoporosis, are unique in that they become physically bound to the bone matrix and 26 
therefore accumulate over time.  This skeletal accumulation has important physiological 27 
implications which are not completely understood.  Objective: To review concepts related 28 
to the biological effects of BP accumulation within the skeleton.  Methods:  Articles 29 
concerning the topic of skeletal accumulation of BP treatment were identified.  30 
Results/Conclusions:  Skeletal accumulation of BP, dictated by both chemical and 31 
biological factors, is dose-dependent, differs among skeletal sites, and likely differs 32 
among the various BPs.  BP embedded within the skeletal matrix has lasting biological 33 
effects, the results of which have both positive and negative implications for bone 34 
remodeling.  As alternative anti-remodeling agents gain approval for treatment of 35 
osteoporosis, the property of skeletal accumulation will likely be unique to 36 
bisphosphonates and therefore may be the property that determines the future use of this 37 
drug class.   38 
 39 
 40 
 41 
 42 
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1.  Introduction 48 
Bisphosphonates (BPs) have become the gold-standard pharmacological treatment for 49 
osteoporosis, numerous other metabolic bone diseases, and for reducing skeletal 50 
complications associated with cancers [1, 2].  BPs produce their effect, whether it be 51 
reducing fracture risk in postmenopausal women or reducing hypercalceimia of 52 
malignancy in cancer patients, by suppressing bone remodeling [2].  Although other 53 
pharmaceutical agents exist for reducing bone remodeling (estrogen/hormone 54 
replacement therapy, calcitonin, selective estrogen receptor modulators), BPs produce the 55 
most robust reduction in bone remodeling.   56 
 57 
The mechanism of action for BPs on bone has recently been expertly reviewed [1].  In 58 
summary, after uptake by osteoclasts via endocytosis, nitrogen-containing BPs (e.g. 59 
alendronate, risedronate, pamidronate, ibandronate, zoledronate) inhibit key enzymes in 60 
the mevalonate pathway, preventing the generation of lipids necessary for the prenylation 61 
of small GTPase proteins.  This in turn results in a significant reduction in the ability of 62 
osteoclasts to resorb bone and therefore a reduction in bone loss.  Non-nitrogen 63 
containing BPs (etidronate, clodronate) act through an alternative mechanism, in which 64 
toxic metabolites, resembling ATP, accumulate and ultimately result in reduced 65 
resorption and bone loss.  These mechanisms of remodeling suppression (either inhibition 66 
of protein prenylation or accumulation of toxic metabolites) are unique to BPs, as 67 
compared to other anti-remodeling agents such as estrogen or calcitonin.  BPs have an 68 
additional uniqueness among the numerous anti-osteoporosis agents in that they are 69 
retained within the body long-term.  Due to their high skeletal affinity and strong binding 70 
properties, BPs become physically bound to the bone matrix.  This skeletal accumulation 71 
has important physiological implications which are not completely understood.   72 
 73 
2.  The chemistry and biology of bisphosphonate accumulation in the skeleton 74 
2.1 Chemistry.  Bisphosphonates all have a common phosphate - carbon - phosphate (P-75 
C-P) moiety as part of their basic structure [3].  While the central portion of the BP 76 
structure is analogous to that of naturally occurring inorganic pyrophosphate, the 77 
substitution of a central carbon atom in BPs for the central oxygen atom of 78 
pyrophosphates confers a resistance to chemical and enzymatic breakdown [4].  This 79 
allows BPs to either bind to the skeleton or be excreted.  Attached to the central P-C-P 80 
core are two side chains (termed R1 and R2).  Each BP differs in its side-chains, which 81 
are primarily responsible for the binding affinity to mineral and biochemical activity on 82 
osteoclast enzyme activity.   83 
 84 
The mineral binding affinity of the BPs determines the probability of attachment to 85 
mineral and the strength of the binding.  Using in vitro methods, the binding affinities of 86 
several BPs to mineral has been established as clodronate < etidronate < risedronate < 87 
ibandronate < alendronate < pamidronate < zoledronate [5, 6].  This means that all things 88 
being equal, zoledronate would have the greatest attraction for and strongest attachment 89 
to mineral.  In addition to the strength of mineral attachment, BPs show different 90 
accumulation capacities for binding to mineral in vitro which result from differences in 91 
electrical charges [5].  Those BPs with more positive charges (alendronate, ibandronate, 92 
zoledronate) are thought to have greater accumulation potential than those with more 93 
negative charges (risedronate) [5].  It is hypothesized that this effect of surface charge 94 
alterations may play a role, independent of mineral affinity, in binding capacity and 95 
therefore skeletal accumulation [1].  This elegant work highlights the complexity of the 96 
physical-chemical properties of BPs which serves as the foundation underlying skeletal 97 
accumulation of BP.  Yet equally important, and equally complex, for determining 98 
skeletal accumulation are the various biological aspects of in vivo administration. 99 
 100 
2.2 Biology.   The high affinity of bisphosphonates for hydroxyapatite results in the 101 
majority of the drug becoming bound to the skeleton upon dosing with the remaining 102 
being cleared, unmetabolized, primary through the kidney.  While in the circulation, 103 
bisphosphonates bind the plasma proteins, predominantly serum albumin, in a 104 
concentration-, pH-, and-calcium concentration- dependent fashion [7, 8].  Based on data 105 
from several species (rats, dogs, monkeys) between 56-66% of BP is retained in the 106 
skeleton 24 hr post dose, the majority of which is incorporated within the first 6 hours 107 
[9].    For a given dose the skeletal uptake of BP is saturable yet for repeated dosing it is 108 
non-saturable [10].  Using a wide range of doses (0.1 to 50 mg/kg), administered to rats 109 
as a single IV injection, there was a linear relationship between dose and skeletal 110 
concentration up to 5 mg/kg with a less than proportional increase thereafter [10].  111 
Interestingly similar skeletal saturation does not occur when high doses (e.g. those that 112 
show saturation with a single dose) are broken up into multiple doses [10].  Several 113 
longer-term experiments confirm this lack of skeletal saturation with repeated dosing in 114 
both rat and dog models [10-16].  This means consideration of cumulative dose, as 115 
opposed to amount of drug for each dose, is the key factor when considering skeletal 116 
accumulation. 117 
   118 
In addition to dose, the route of administration plays a significant role in determining 119 
skeletal accumulation.  A major limitation of oral dosing is the low bioavailability, the 120 
amount of drug that reaches the systemic circulation.  Interesting, oral absorption which 121 
occurs primarily in the stomach and upper aspect of the small intestine [17, 18], is non-122 
linearly dose-dependent; increasing the oral dose from 2 to 40 mg/kg results in changes in 123 
bioavailability of the drug from 0.5% to 5% [18].  This has potentially significant 124 
implications with respect to the trend toward higher, less frequent dosing regimens.  For 125 
example, oral alendronate can be taken as a daily (10mg) or weekly (70mg) dose; ora 126 
risedronate as a daily (5 mg), weekly (35 mg), or monthly (150 mg) dose; ibandronate 127 
can be taken as a daily (2.5 mg) or monthly (150 mg) oral dose or a quarterly (3 mg) 128 
intravenous dose.  This means that skeletal accumulation in patients treated early in the 129 
life of alendronate (daily dosing) is likely lower than those treated with the more recent 130 
weekly dosing.  The transition to intravenous dosing, which overcomes the low 131 
bioavailability of oral dosing, also leads to significantly higher levels of skeletal 132 
accumulation relative to oral dosing [9].  Even when attempts have been made to match 133 
bioavailability between oral and intravenous dosing (giving 10-fold higher doses orally) 134 
there was still 10-fold higher plasma concentration and a 30-fold higher concentration of 135 
skeletally-bound BP with IV dosing [19].  These disproportional changes suggest there 136 
are additional effects, beyond just higher plasma concentrations, related to intravenous 137 
dosing that dictate skeletal uptake. 138 
 139 
Skeletal accumulation of BP is not homogenous across bone sites.  Although limited data 140 
exists, sites with higher remodeling are thought to accumulate greater amounts of drug 141 
[12].  The accumulation at such sites is postulated to be due to a greater amount of 142 
actively resorbing surface which is known to preferentially bind BP [20].  Alternatively, 143 
it could be that sites with higher remodeling have greater metabolic demands and thus 144 
have higher blood flow.  It has been shown that the site-specificity of BP accumulation is 145 
dose [14] and duration dependent [21].  It is also plausible that there may be differences 146 
in site-specificity among the bisphosphonates and/or by route of administration 147 
highlighting the complexity and interaction among all the biological factors. 148 
 149 
Another important consideration with respect to accumulation of BP is the disassociation 150 
of bound drug from the skeleton.  In vitro, hydroxyapatite-bound BP is liberated during 151 
resorption due to the locally acidic environment produced by the osteoclasts [20].  Data 152 
concerning dissociation come from two different dog studies.  Following one year of 153 
treatment with pamidronate, animals were allowed an additional year of treatment 154 
withdrawal followed by assessment of skeletal concentrations in the ilium, stenum, and 155 
vertebra [14].  Although all bone sites had significantly less pamidronate at year 2 156 
compared to year one, the change was greatest in the vertebra [14].  Similar results were 157 
found in the rib in studies using etidronate [22].  These data  suggests the dissociation is 158 
greatest at sites with the highest metabolic activity even if that activity had been reduced 159 
by BP-treatment. 160 
 161 
Taken together, these data begin to unravel the mechanisms, both chemical and 162 
biological, underlying skeletal accumulation of BP.  The underpinning is clearly in the 163 
physical interaction between BP and hydroxyapatite brought about by the chemical 164 
structure/charge.  Yet accumulation is strongly dependent on biological aspects including 165 
dosing level, route of administration, skeletal sites, duration of treatment, as well 166 
interactions among these factors.  To add another level of complexity, each BP has its 167 
own chemical and biological properties making it necessary to consider each of them 168 
separately [17].  Thus while each property, specifically those related to the biological 169 
aspects of accumulation, have been worked out for some of the BPs, the results are not 170 
likely applicable to all BPs. 171 
 172 
3.  The clinical implication of bisphosphonate accumulation in the skeleton 173 
The focus on skeletal accumulation of bisphosphonates is ultimately aimed at 174 
understanding if/how it affects skeletal health.  BP within the skeleton retains the ability 175 
to exert anti-remodeling effects once it is liberated from the skeleton.  This has 176 
significant implications with respect to determining whether and how to treat patients’ 177 
long term.  Specifically, the question is whether it is necessary for indefinite treatment or 178 
whether drug holidays (periodic cessation of treatment) could be utilized without 179 
compromising efficacy.  Additionally as data suggests reduced efficacy of anabolic 180 
agents in patients who have been treated with BPs, it is important to understand how 181 
effectively BP-induced remodeling suppression reverts to basal levels if alternative 182 
pharmaceutical treatments are warranted.  Although these two concepts represent the 183 
majority of clinical interest in bisphosphonate accumulation, the concept of skeletal 184 
accumulation has been brought to the forefront of bisphosphonate research recently with 185 
the emergence of a condition known as osteonecrosis of the jaw (ONJ).  Despite the lack 186 
of a definitive cause/effect relationship between BPs and ONJ, much speculation exists 187 
concerning such a relationship and this speculation involves skeletal accumulation of BP 188 
as a contributing factor.    189 
 190 
3.1 Continued remodeling suppression and fracture risk reduction following 191 
bisphosphonate treatment withdrawal 192 
The most definitive clinical data concerning the skeletal effects following withdrawal of 193 
BP-treatment come from a recent study of Black et al [23].  Building on the initial 194 
Fracture Intervention Trial (FIT) study which treated patients for 5 years with placebo or 195 
alendronate [24, 25], the Fracture Intervention Trial Long-term Extension (FLEX) was 196 
designed to follow a subset of alendronate-treated patients for an additional 5 years with 197 
either continued alendronate treatment or placebo [23].  The results of this study show 198 
that women who were switched to placebo treatment lost a significant amount of bone 199 
density over the 5 year period although their BMD remained well-above baseline values.  200 
Biomarkers of bone remodeling of patients who stopped alendronate treatment were 201 
higher than those of patients who continued treatment, yet also remained significantly 202 
lower compared to baseline.  While this study was not powered to detect differences in 203 
fractures between the two groups, there was not even a trend toward differences in 204 
clinical fractures between women who stopped treatment compared to those who 205 
continued.  Subsequent subgroup analyses, again limited by statistical power, suggest 206 
women at the highest risk of fracture benefit most from continued treatment while those 207 
with adequate response to 5 years of treatment could be considered for a drug holiday.  208 
The ideal duration for such a drug holiday, or criteria by which to base resuming 209 
treatment, were not addressed by the authors.  Despite the limitation concerning power to 210 
detect fractures, this study is significant as it is likely to be the best data to be generated 211 
concerning treatment withdrawal [26] unless similar extensions of large-scale follow-ups 212 
to other clinical trials are undertaken.  Other retrospective data concerning withdrawal 213 
from BP-treatment do suggest there may be a minimal treatment duration prior to 214 
withdrawal that is necessary in order to have sustained fracture risk efficacy [27].  Those 215 
patients treated for 2 years at the time of treatment withdrawal had significantly higher 216 
number of fractures compared to those who continued treatment; this was not the case in 217 
patients treated >2 years prior to withdrawal [27, 28].  Taken together, these limited data 218 
provide support for drug holidays in some BP-treated patients, most notably those who 219 
have been treated for several years with robust BMD responses to these years of 220 
treatment.  221 
 222 
Additional smaller sets of clinical data do exist regarding bone turnover biomarkers 223 
and/or BMD after treatment withdrawal.  These studies show that upon treatment 224 
withdrawal, the rate of bone density decline is similar in patients previously treated with 225 
alendronate as those treated with placebo although the alendronate-treated patients 226 
remain with higher BMDs [29, 30].  Additionally, numerous studies show that although 227 
bone turnover biomarkers revert back toward placebo-treated patient levels after 228 
withdrawal they remain significantly lower up to seven years post-withdrawal [29-33].  229 
An important factor, given the clear difference in skeletal accumulation among the 230 
different bisphosphonates, is that the majority of clinical data concerning treatment 231 
withdrawal are in patients treated with daily oral alendronate.  As other bisphosphonates 232 
and other treatment regimens gain sufficient patient populations, clinical data may 233 
become available in the future. 234 
 235 
Pre-clinical studies provide data on the effects of BP withdrawal that complement these 236 
clinical studies.  Using ovariectomized rats, the benefits of risedronate on trabecular bone 237 
mass preservation and suppression of bone remodeling that occurred following 6 months 238 
of treatment were maintained through 6 months of withdrawal but, in general, were 239 
completely lost after 12 months [34].  These findings are supported by studies with 240 
incadronate, which additionally showed that changes during withdrawal were dose 241 
dependent as higher doses maintained benefits four times longer upon withdrawal [35].  242 
In the lone pre-clinical comparison between two BPs, ovariectomized rats were treated 243 
with either alendronate or risedronate (at doses consistent with those used clinically on a 244 
mg/kg basis) for 8 weeks and then withdrawn for up to 16 weeks [36].  This study 245 
showed trabecular bone formation rate returned to levels comparable to controls in 246 
risedronate, but not alendronate treated animals [36].  These data highlight the BP-247 
specific responses to treatment withdrawal, which the authors postulated could be the 248 
result of different binding affinities between the two drugs.  Overall, these pre-clinical 249 
data support the clinical studies in showing that 1) there is a clear effect of treatment dose 250 
and/or duration on the withdrawal response and 2) each bisphosphonate is likely different 251 
in these responses. 252 
 253 
3.2 Influence of continued remodeling suppression during treatment withdrawal on 254 
subsequent anabolic efficacy 255 
The residual effects of continued remodeling suppression following BP-treatment do not 256 
come without a cost, one of which is a potential compromised response to subsequent 257 
treatment with anabolic agents.  Anabolic treatment for osteoporosis, of which 258 
parathyroid hormone (PTH) is currently the only FDA approved agent, stimulate bone 259 
modeling/remodeling to increase bone mass and is indicated for patients with severe 260 
osteoporosis.  The most likely scenario in which anabolic treatment would follow 261 
bisphosphonate treatment is if a patient fails to adequately respond to BP-treatment and 262 
necessitates other means of enhancing bone mass.  The clinical data show that when PTH 263 
is given either concurrently with [37, 38] or after cessation of [39, 40] alendronate, there 264 
is a significant blunting of the anabolic effect as determined by changes in BMD and 265 
remodeling biomarkers.  Interesting, the same is not true following treatment with 266 
risedronate which, when withdrawn, allows significant PTH-induced increases in bone 267 
turnover markers and BMD [40].  These bisphosphonate-specific interactions with 268 
anabolic treatment are supported by pre-clinical studies [41]. 269 
 270 
3.3 Proposed connection between skeletal accumulation and osteonecrosis of the jaw 271 
The condition of osteonecrosis of the jaw (ONJ) continues to be an enigma surrounding 272 
BP-treatment, albeit predominately within the context of high doses to cancer patients 273 
[42, 43].  Despite the lack of definitive proof directly linking BPs and ONJ, enough 274 
indirect evidence exists to justify discussion of potential mechanisms underlying this 275 
condition.  It has been hypothesized that the focal loss of osteocytes [44] [45] and their 276 
canalicular network [45] with BP-treatment are a part of ONJ pathophysiology [46].  277 
Loss of osteocyte viability could simply be an unintended consequence of reduced 278 
remodeling, which would allow regions containing osteocytes that die of normal causes 279 
to accumulate over time.  The remodeling rate of the mandible is one of the highest 280 
among skeletal sites [47, 48] and therefore the significant reduction in remodeling that 281 
occurs in the mandible with BP-treatment [45] would lead to the natural accumulation of 282 
non-viable regions.  If this is the mechanism through which regions of necrosis develop, 283 
then the issues described above with respect to recovery of bone remodeling following 284 
treatment withdrawal become imperative with respect to ONJ treatment and prevention.   285 
 286 
An alternative explanation for accumulation of non-viable osteocytes is through a more 287 
direct pathway in which BPs have direct cytotoxic effects on osteocytes [46, 49].  In vitro 288 
studies have shown that when cultured in high concentrations of bisphosphonate, nearly 289 
every cell type has the capacity to internalize the drug, which in turn results in cell death.  290 
The effects of BPs on osteogenic cells (osteoblasts/osteocytes) in culture show a clear 291 
dose-dependent response with low concentrations suppressing apoptosis [50] and higher 292 
concentrations enhancing apoptosis [51].  The fundamental question underlying the idea 293 
of BPs having cytotoxic effects of osteocytes therefore lies in whether or not these 294 
matrix-entombed cells are exposed to sufficient concentrations of the drug.  Conventional 295 
wisdom is that in vivo, BPs are localized predominately to bone surfaces adjacent to 296 
marrow (endocortical and trabecular surfaces), with preferential binding to sites actively 297 
undergoing resorption and formation [20, 52].   Recently, however, it has been shown 298 
that systemically administered bisphosphonate reaches, and becomes embedded in, the 299 
walls of osteocyte lacunae [53].  Despite this proof-of-concept showing that BPs have 300 
access to the osteocyte-canalicular network in vivo, it remains unknown whether or not 301 
sufficient quantities accumulate that could have cytotoxic effects on the resident 302 
osteocytes.   303 
 304 
4.  Future Directions 305 
Future interest concerning skeletal accumulation of bisphosphonates is dependent on the 306 
overall interest in bisphosphonates as an osteoporosis treatment.  In turn, interest in 307 
bisphosphonates as a treatment may depend on the biological effects of skeletal 308 
accumulation.  Several newer generation anti-osteoporotic treatments are on the horizon 309 
and although not yet approved by the FDA, these agents are likely to reduce fracture risk 310 
through mechanisms which differ from bisphosphonates.  It is unlikely, however, that 311 
future agents will accumulate in the skeleton leaving this a property that will remain 312 
unique to bisphosphonates.   313 
 314 
Skeletal accumulation may ultimately dictate the role bisphosphonates play in skeletal 315 
biology, both related to osteoporosis treatment as well as in other metabolic bone 316 
condition.  As such much work needs to be done to understand 1) key properties of 317 
skeletal accumulation for newer generation bisphosphonates, 2) the residual biological 318 
effect of all bisphosphonates following treatment withdrawal as it relates to drug holidays 319 
and 3) any potential adverse effects associated with skeletal accumulation.  The newest 320 
generation of bisphosphonates, ibandronate (either monthly oral or quarterly intravenous 321 
dosing) and zoledronate (yearly intravenous dosing), lack data concerning skeletal 322 
accumulation.  As these specific bisphosphonates utilize higher, less frequent dosing as 323 
well as different routes of administration compared to the more traditional 324 
bisphosphonates (risedronate and alendronate), it is essential to understand how these 325 
specific agents, dosing levels, and dosing routes influence skeletal accumulation.  The 326 
need for greater understanding of residual effects of bisphosphonates following treatment 327 
withdrawal is true for all bisphosphonates.  Specifically, it will be important to 328 
understand how treatment duration influences the withdrawal response and whether or 329 
not there are different optimal durations of treatment if the goal is to sustain an effect 330 
following treatment withdrawal as opposed to if the goal is to reverse an effect upon 331 
withdrawal. Finally, it is essential to determine if there are any adverse effects associated 332 
with skeletal accumulation and therefore any benefits to utilizing drug holidays.  The 333 
emergence of jaw necrosis associated with bisphosphonate treatment, most notably in 334 
patients treated with high intravenous doses for cancer therapy, has sparked concern 335 
about potential adverse effects of accumulation although this hypothesis remains 336 
untested.  Whether or not there is merit to this hypothesis, the general understanding of 337 
the long-term biological consequences of skeletal accumulation on bone cells is certainly 338 
warranted.    339 
 340 
Many of these questions are limited by the difficulty in measuring BP concentrations in 341 
biological tissues.  Much of the pre-clinical data on alendronate utilized radioactive-342 
labeled drug [9, 10, 52] which presents unique challenges for many laboratories and also 343 
could limit its transition to large animal models and to humans.  It is possible to measure 344 
BP concentrations in biological fluids and then estimate concentrations in the skeleton 345 
although this does not allow differences among skeletal sites to be investigated [54].  346 
Skeletal extraction and quantification of BP, although possible, is not widely utilized due 347 
to the need for specialized equipment and technical expertise [13, 55].  An emerging area 348 
of advancement is imaging of bisphosphonates that have been fluorescently-tagged.  349 
These techniques include bulk assessment of skeletal accumulation [56, 57], histological 350 
imaging of fluorescent signal [57-60] and, most excitingly, non-invasive in vivo imaging 351 
[57, 61].  Future work in this field could significantly boost the understanding of BP 352 
accumulation in the skeleton.   353 
 354 
5.  Conclusions 355 
Skeletal accumulation of bisphosphonates, driven by both chemical and biological 356 
factors, is dose-dependent, skeletal site-specific, and differs among the various 357 
bisphosphonates.  Once embedded within the matrix, bisphosphonates can be liberated by 358 
osteoclast-mediated bone resorption, effectively recycling the drug in an active form.  359 
This drug recycling leads to continued remodeling suppression, and an apparent 360 
continued reduction in fracture risk following treatment withdrawal.  Although these 361 
sustained effects seems to require some minimal duration of treatment prior to 362 
withdrawal, there is increasing evidence to support the concept of bisphosphonate ‘drug 363 
holidays’, especially in those patients who robustly respond (based on BMD) to the initial 364 
years of treatment.  Continued remodeling suppression following treatment withdrawal, 365 
which differs among the various bisphosphonates, blunts the effect of anabolic treatments 366 
which could be a significant drawback in patients that necessitate alternative means of 367 
increasing bone mass.  The recent implication of skeletal accumulation in the 368 
pathophysiology of jaw osteonecrosis has also raised concern about long-term 369 
consequences of skeletal accumulation although data are completely lacking on this 370 
subject.  As new generation anti-remodeling agents begin to emerge, the property of 371 
skeletal accumulation will likely be unique to bisphosphonates and therefore could be the 372 
property that determines the future use of this drug class.   373 
 374 
6.  Expert Opinion 375 
Bisphosphonates have revolutionized the prevention and treatment of osteoporosis while 376 
simultaneously helping advance the basic understanding of skeletal biology.  While quite 377 
a bit is known about bisphosphonates, there is much that remains unknown including 378 
nearly all aspects related to skeletal accumulation.  The idea of skeletal accumulation has 379 
been acknowledged since the inception of BPs with some of the most in-depth studies 380 
concerning this issue conducted in the early years of BP development.  These pre-clinical 381 
studies highlighted that skeletal accumulation is a multi-factorial process, dictated by 382 
dose, route of administration and duration of treatment.  Subsequently, as newer 383 
generation bisphosphonates have entered the market, it has become clear that differences 384 
exist in the kinetics and biological consequences of bisphosphonate skeletal 385 
accumulation.  In fact, skeletal accumulation differences and their associated biological 386 
effects may be the most prominent distinguishing feature among the various 387 
bisphosphonates.  With additional understanding of skeletal accumulation differences 388 
among the various bisphosphonates, it could be possible use specific bisphosphonate for 389 
patients depending on their situation.   For example, if the goal is only transient 390 
suppression of remodeling or if there is a potential for anabolic treatment in the future, a 391 
bisphosphonate which has accumulation properties that favor more rapid reversal may be 392 
preferred.  Conversely, for a patient who is perceived to necessitate long-term remodeling 393 
suppression might be better served using a bisphosphonate which has sustained effects 394 
after withdrawal.  The latter scenario could also incorporate intermittent drug holidays 395 
into the treatment regimen.   396 
 397 
Neither the risk nor the benefits of drug holidays are truly understood.  Although clinical 398 
data concerning bisphosphonate drug holidays are limited, they are encouraging in that 399 
fracture risk reductions can be maintained in certain patients.  Thus, it seems warranted 400 
for physicians to consider their use especially for patients who have been treated with 401 
alendronate and have shown a robust BMD response. The data for risedronate suggest a 402 
more rapid loss of BP effect upon withdrawal, while no data exist for the other 403 
bisphosphonates, making the use of drug holidays in patients treated with these BPs less 404 
clear.  If drug holidays are undertaken, vigilance is necessary on the part of the health 405 
care provider to track BMD and/or biomarker data and resume treatment when such 406 
markers dictate.  Unfortunately, there are no established criteria for at what point to 407 
resume treatment.  Given the difficulty associated with defining such criteria, they may 408 
never exist.   409 
 410 
So the question ultimately becomes whether there is any benefit to a drug holidays.  The 411 
safety profile of bisphosphonates has been exemplary and as such there has been little 412 
need to seriously explore drug holidays.  The emergence of jaw necrosis, as well as 413 
recent reports of atypical femoral fractures, has sparked concern with respect to safety, 414 
specifically over the long term.  The exact role of BP-treatment in general, and more 415 
specifically skeletal accumulation, is unclear in both of these situations.  Even if they do 416 
play a role, however, it isn’t clear that temporarily cessation of treatment would have any 417 
effect.  Until these two aspects are clarified, the benefit of bisphosphonate drug holidays 418 
should be considered minimal.  This means that at this point, while there is little risk to 419 
utilizing drug holidays is select patients, there is also little clear benefit. 420 
 421 
Bisphosphonates will likely remain a mainstay for treating metabolic bone diseases in the 422 
near future.  Given the unique property of skeletal accumulation among anti-remodeling 423 
agents, they could potentially retain a significant role for much longer.  However, in 424 
order to do so, additional work must be undertaken to understand the intricacies of 425 
skeletal accumulation and how to best utilize it to serve the needs of patients. 426 
 427 
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